Abnormalities in the expression of cytokines and their receptors in patients with myelodysplastic syndromes.

被引:0
|
作者
FontenayRoupie, M
Dreyfus, F
机构
来源
PATHOLOGIE BIOLOGIE | 1997年 / 45卷 / 07期
关键词
cytokines; receptors;
D O I
暂无
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Abnormalities of the expression of cytokines and their receptors seen in myelodysplastic syndromes (MDS) are reviewed. Autocrine and paracrine secretion of growth factors, most notably GM-CSF and IL-6, has been identified as a factor in clone expansion in young pediatric patients with chronic myelomonocytic leukemia. Mutations affecting cFMS, the receptor for M-CSF, have also been demonstrated. The other reported abnormalities have been found in too small a number of cases to explain the cell growth and differentiation disorders seen during the course of MDS. It remains possible, however, that a more detailed study of signal transduction pathways might detect functional abnormalities explaining the contrast between the small number of reported cases with abnormalities at the cytokine and cytokine receptor sites and the cell growth and differentiation disorders that are prominent in MDS.
引用
收藏
页码:569 / 572
页数:4
相关论文
共 50 条
  • [1] Molecular abnormalities and clonality in myelodysplastic syndromes.
    Fenaux, P
    Preudhomme, C
    PATHOLOGIE BIOLOGIE, 1997, 45 (07): : 556 - 560
  • [2] Pathogenesis of immunological abnormalities in myelodysplastic syndromes.
    Okamoto, T
    Okada, M
    Takemoto, Y
    Kanamaru, A
    Kakishita, E
    BLOOD, 1997, 90 (10) : 2316 - 2316
  • [3] Immunological abnormalities in myelodysplastic syndromes. Prospective study (series of 40 patients)
    Bouali, F
    Berrah, A
    Ahmed-Bouali, DS
    Harrieche, F
    Benhalima, M
    Hamladji, RM
    Arrada, M
    REVUE DE MEDECINE INTERNE, 2005, 26 (10): : 777 - 783
  • [4] Myelodysplastic syndromes.
    Miller K.B.
    Current Treatment Options in Oncology, 2000, 1 (1) : 63 - 69
  • [5] Increased expression of Fas antigen and apoptosis in patients with myelodysplastic syndromes.
    Okada, M
    Okamoto, T
    Saheki, K
    Fujimori, Y
    Takemoto, Y
    Kakisita, E
    BLOOD, 1997, 90 (10) : 893 - 893
  • [6] Terminal deoxynucleotidyl transferase expression in myelodysplastic syndromes.
    Fan, G
    Mazzella, FM
    KowalVern, A
    Wibowo, A
    Mikhael, A
    Schumacher, HR
    BLOOD, 1997, 90 (10) : 4037 - 4037
  • [7] Impact of immunophenotype on prognosis of patients with myelodysplastic syndromes.: Its value in patients without karyotypic abnormalities
    Arroyo, JL
    Fernández, ME
    Hernández, JIM
    Orfao, A
    San Miguel, JF
    del Cañizo, MC
    HEMATOLOGY JOURNAL, 2004, 5 (03) : 227 - 233
  • [8] Measurement of mRNA expression for a variety of cytokines and its receptors in bone marrows of patients with myelodysplastic syndromes
    Allampallam, K
    Shetty, V
    Hussaini, S
    Mazzoran, L
    Zorat, F
    Huang, RW
    Raza, A
    ANTICANCER RESEARCH, 1999, 19 (6B) : 5323 - 5328
  • [9] RAS and the myelodysplastic syndromes.
    Gallagher, A
    Darley, R
    Padua, RA
    PATHOLOGIE BIOLOGIE, 1997, 45 (07): : 561 - 568
  • [10] Apoptosis in myelodysplastic syndromes.
    Pearsall, CP
    Kroft, S
    Ross, C
    Schnitzer, B
    Singleton, TP
    LABORATORY INVESTIGATION, 1997, 76 (01) : 767 - 767